Ben Fulton, Susan C. Short, Allan James, Stefan Nowicki, Catherine McBain, Sarah Jefferies, Caroline Kelly, Jon Stobo, Anna Morris, Aoife Williamson, Anthony J. Chalmers
Abstract
Rights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
10.1016/j.ejca.2012.12.027 · 2013
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005
MGMT gene silencing and benefit from temozolomide in glioblastoma
10.1056/nejmoa043331 · 2005
AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
10.1007/s12325-011-0007-3 · 2011
A randomized trial of bevacizumab for newly diagnosed glioblastoma
10.1056/nejmoa1308573 · 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70379-1 · 2014
2010 Society for neuro-oncology annual meeting: a report of selected studies
10.1586/era.10.227 · 2011
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
10.1200/jco.2008.17.5984 · 2009
Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas
10.1038/onc.2010.249 · 2010
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1038/nature05236 · 2006
PARP-1 protein expression in glioblastoma multiforme
10.4081/ejh.2012.e9 · 2012
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors
10.2174/187152010793498627 · 2010
The potential of PARP inhibitors in neuro-oncology
10.2217/cns.12.13 · 2012
“Replication-dependent radiosensitisation of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential
10.1016/j.ijrobp.2008.07.031 · 2008
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA syntheses
10.1158/1535-7163.mct-05-0418 · 2006
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
10.1007/s00280-013-2113-1 · 2013
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
10.1093/annonc/mdv308 · 2015
Poly(ADP-ribosyl)ation enzyme-1 as a target for neuroprotection in acute central nervous system injury
10.2174/1568007033482733 · 2003
Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain
10.1667/rr2587.1 · 2011
MGMT testing – the challenges for biomarker-based glioma treatment
10.1038/nrneurol.2014.100 · 2014
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
10.1158/1078-0432.ccr-15-3153 · 2016
No additional external references are available.
